Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies

NCT05205252 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT05205252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Epizyme, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 22, 2021
Completion date
July 5, 2023
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory hematologic malignancy, relapsed hematologic malignancy